Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
Overview
- Phase
- Not Applicable
- Intervention
- intra-arterial administration of melphalan
- Conditions
- Retinoblastoma
- Sponsor
- Istanbul University - Cerrahpasa (IUC)
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- globe salvage
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute.
The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
Investigators
Bilge Batu Oto
Ophthalmology Specialist, Medical Doctor
Istanbul University - Cerrahpasa (IUC)
Eligibility Criteria
Inclusion Criteria
- •patients diagnosed with unilateral/bilateral retinoblastoma
Exclusion Criteria
- •patients with trilateral retinoblastoma
- •extraoculer involvement
- •patients with blood dyscrasias, bleeding and clotting disorders
Arms & Interventions
group 1
Patients who received intra-arterial chemotherapy as a first line treatment
Intervention: intra-arterial administration of melphalan
group 2
Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
Intervention: intra-arterial administration of melphalan
Outcomes
Primary Outcomes
globe salvage
Time Frame: 2-5 years
globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma